{"schema_version":"secwatch.filing_event.v1","accession":"0001821586-25-000021","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.616935+00:00","generated_at":"2026-05-17T00:23:34.522833+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MoonLake Q3 2025: $380.5M cash, positive Phase 2 PPP data for Sonelokimab","bullets":["Cash and equivalents $380.5M as of Sept 30, 2025; runway into H2 2027.","R&D expenses $60.6M (up from $49.8M) driven by trial ramp-up and BLA prep.","Phase 2 LEDA PPP: 64% mean PPPASI reduction, 39% PPPASI75 at week 16; no approved therapies.","VELA-TEEN interim: 46% HiSCR75 in adolescent HS at week 16 (n=11); BLA submission Q3/Q4 2026.","FDA Type B meeting Dec 15, 2025 to discuss SLK in HS evidence for BLA."],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-25-000021","json":"https://secwatch.observer/filing/0001821586-25-000021.json","markdown":"https://secwatch.observer/filing/0001821586-25-000021.md","text":"https://secwatch.observer/filing/0001821586-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/0001821586-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/mnlk-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:23:34.522833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}